CYTO: Altamira Therapeutics Ltd. Company Value to Net Income

Corporate emblem and logo of Altamira Therapeutics Ltd. (CYTO)

Altamira Therapeutics (CYTO) is implementing eco-friendly packaging solutions by developing nasal sprays that minimize the use of medical needles. Simultaneously, its R&D center is refining peptide nanoparticles for RNA cellular delivery, establishing a foundation for partnerships with industry behemoths. The price action shown below for securities with the 0.00 indicator complements production data for over-the-counter drugs, where patent protection of formulas ensures consistently high profits.

CYTO Altamira Therapeutics Ltd: Price to Earnings Ratio in the range 07/04/2022 - 11/06/2023

Comprehensive metric breakdowns and analytics for Altamira Therapeutics Ltd (CYTO)

- price and consensus price forecast:
Stock Price Auris Medical|CYTO - Consensus Target
- market capitalization information:
Market Value Altamira Therapeutics Ltd.|CYTO - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Altamira Therapeutics|CYTO - Company Net Assets|Market Cap to Book Value Multiple altamiratherapeutics.com|CYTO - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Altamira Therapeutics|CYTO - Long-Term Debt to Capital|Current Liabilities to Capital Auris Medical|CYTO - Company Debts|Debt to Net Assets Ratio Altamira Therapeutics Ltd.|CYTO - Company Long-Term Debts|Company Short-Term Debts Altamira Therapeutics|Quick Liquidity altamiratherapeutics.com
- business earnings and investment ratios data:
CYTO - Net Income|Future Net Profit Altamira Therapeutics|CYTO - P/E Multiple|Forward P/E Multiple Auris Medical|CYTO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Altamira Therapeutics Ltd.|CYTO - Operating profit EBITDA|Net earnings per share for the last four quarters Altamira Therapeutics|CYTO - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months altamiratherapeutics.com|CYTO - Earnings growth in current year|Earnings growth forecast for next year Altamira Therapeutics
Comprehensive company analysis:altamiratherapeutics.com - CYTO
Flagship merchandise of Altamira Therapeutics Ltd.

The effectiveness of the R&D strategy of Altamira Therapeutics (CYTO) in the field of RNA delivery is reflected in the company's fundamental P/E ratio. This indicator correlates the market value of the share with net income, determining the payback period for investments. The calculation allows for an assessment of how much an investor pays for a unit of the business's current earnings. High costs associated with retaining leading molecular biologists directly impact the final value of this metric. Analysis of the indicator confirms a balance between capital protection and the growth potential of the assets.

Key competitors

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|P/E Multiple PCRX (Pacira BioSciences, Inc.)|P/E Multiple ARS Pharmaceuticals Inc SPRY|TBPH - Price to Earnings Ratio|AQST: Price to Earnings Ratio|SCPH (scpharmaceuticals.com) - Price to Earnings Ratio|TECX: Market Price to Net Income Ratio|TNXP (Tonix Pharmaceuticals Holding Corp.) - P/E Multiple|P/E Multiple SXT China|Price to Earnings Ratio Eupraxia Pharmaceuticals (EPRX)|Price to Earnings Ratio BioHarvest Sciences Inc BHST|P/E Multiple EXOZ (eXoZymes Inc)|Business Payback Period Oramed (ORMP)|ENTX - Price to Earnings Ratio|Company Value to Net Income HYFT (MindWalk Holdings, Inc.)|ABVC: P/E Multiple|Cumberland Corp (CPIX) - P/E Multiple|Price to Earnings Ratio QNTM|FGEN: Company Value to Net Income|Price to Earnings Ratio TELO (Telomir Pharmaceuticals, Inc.)|Market Price to Net Income Ratio RANI|P/E Multiple SNYR (Synergy CHC)|Company Value to Net Income RLYB|Lexaria - P/E Multiple|Market Cap to Earnings pulmatrix.com|ftzy.com.cn (PTHL) - Price to Earnings Ratio|Aptorum Group - Company Value to Net Income|LYRA (Lyra Therapeutics, Inc) - P/E Multiple|P/E Multiple Impact BioMedical, Inc.|Price to Earnings Ratio TNF Pharmaceuticals (TNFA)|YCBD: Market Cap to Net Income|P/E Multiple PRFX (PainReform)|Lipella Pharmaceuticals Inc (LIPO) - Market Cap to Earnings|OPTN: Price to Earnings Ratio|PIRS - P/E Multiple|PROC (Procaps Group S.A.) - Price to Earnings Ratio|PTPI: Market Price to Net Income Ratio|QLI (Qilian International Holding) - P/E Multiple|Acelyrin Inc. (SLRN) - Business Payback Period|P/E Multiple TFFP